Neurocrine Biosciences (NBIX)
(Delayed Data from NSDQ)
$147.45 USD
-0.01 (-0.01%)
Updated Jul 16, 2024 04:00 PM ET
After-Market: $148.12 +0.67 (0.45%) 7:58 PM ET
2-Buy of 5 2
D Value C Growth A Momentum C VGM
Brokerage Reports
Neurocrine Biosciences, Inc. [NBIX]
Reports for Purchase
Showing records 261 - 280 ( 311 total )
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
KINECT 2 Gives Back More Than KINECT 1 Took Away
Provider: Roth Capital Partners, Inc.
Analyst: HAZLETT R
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: NAPODANO J
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
MORNING CALL SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
MID-DAY SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: NAPODANO J
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
MORNING CALL SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: NAPODANO J
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
MORNING CALL SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: NAPODANO J
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
MORNING CALL SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
Transferring Coverage and Placing Under Review
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
MORNING CALL SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
1Q13 - KINECT and KINECT-II Data Releases in 2H13 Are The Focus
Provider: Roth Capital Partners, Inc.
Analyst: JEN Y
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: NAPODANO J
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
MORNING CALL SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
Former Announcement of the Start of Elagolix in UF Phase IIb Study
Provider: Roth Capital Partners, Inc.
Analyst: JEN Y
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
MORNING CALL SUMMARY
Provider: Roth Capital Partners, Inc.